Weiwei Ouyang

Dr. Weiwei Ouyang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SSSheng-Fa Su
Sheng-Fa Su
YHYin-Xiang Hu
Yin-Xiang Hu
WOWeiwei Ouyang
Weiwei Ouyang
BLBing Lu
Bing Lu
ZMZhu Ma
Zhu Ma
YGYi-Chao Geng
Yi-Chao Geng
Background: The role of chemotherapy given concurrently with thoracic three-dimensional radiotherapy for stage IV non-small cell lung cancer (NSCLC) is not well defined. We performed this study to investigate overall survival and toxicity in patients with stage IV NSCLC treated with this modality. Methods: From 2003 to 2010, 201 patients were enrolled in this study. All patients received chemotherapy with concurrent thoracic three-dimensional radiotherapy. The study endpoints were the assessment of overall survival (OS) and acute toxicity. Results: For all patients, the median survival time (MST) was 10.0 months, and the 1-, 2- and 3-year OS rates were 40.2%, 16.4%, and 9.6%, respectively. The MST was 14.0 months for patients who received a total radiation dose ≥63 Gy to the primary tumor, whereas it was 8.0 months for patients who received a total dose <63 Gy (P = 0.000). On multivariate analysis, a total dose ≥63 Gy, a single site of metastatic disease, and undergoing ≥4 cycles of chemotherapy were independent prognostic factors for better OS (P = 0.007, P = 0.014, and P = 0.038, respectively); radiotherapy involving metastatic sites was a marginally significant prognostic factor (P = 0.063). When the whole group was subdivided into patients with metastasis at a single site and multiple sites, a higher radiation dose to the primary tumor remained a significant prognostic factor for improved OS. For patients who received ≥4 cycles of chemotherapy, high radiation dose remained of benefit for OS (P = 0.001). Moreover, for the subgroup that received <4 chemotherapy cycles, the radiation dose was of marginal statistical significance regarding OS (P = 0.063). Treatment-related toxicity was found to be acceptable. Conclusions: Radiation dose to primary tumor, the number of metastatic sites, and the number of chemotherapy cycles were independent prognostic factors for OS in stage IV NSCLC patients treated with concurrent chemoradiotherapy. In addition to systemic chemotherapy, aggressive thoracic radiotherapy was shown to play an important role in improving OS. Trial registration: Registered on (ChiCTR-TNC-10001026)

21 November 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SSShengFa Su
ShengFa Su
YHYinXiang Hu
YinXiang Hu
WOWeiwei Ouyang
Weiwei Ouyang
ZMZhu Ma
Zhu Ma
QLqingsong li
qingsong li
BLBing Lu
Bing Lu
The role of radiation therapy in addition to chemotherapy has not been well established in non-oligometastatic Stage IV non-small cell lung cancer (NSCLC). We aimed to investigate overall survival (OS) of non-oligometastatic Stage IV NSCLC treated with chemotherapy with concurrent radiation to the primary tumor. Eligible patients were screened from two prospective studies. Oligometastatic and non-oligometastatic NSCLC were defined as having < 5 and ≥5 metastatic lesions, respectively. Prognostic factors for OS were identified by using univariate and multivariate analysis. Landmark analysis and propensity-score matching (PSM) were each performed to further adjust for confounding. A total of 274 patients were identified as the study cohort: 183 had non-oligometastatic disease. For all 274 patients, those who received a radiation dose ≥63 Gy to the primary tumor and had oligometastatic disease had better OS (P < 0.001 and P = 0.017, respectively). When patients were subdivided into those with oligometastatic or non-oligometastatic disease, a radiation dose ≥ 63 Gy remained a significant prognostic factor for better OS. For non-oligometastatic patients, multivariate analysis showed that receiving ≥63 Gy radiation, having a GTV <146 cm3, having response to chemotherapy, and having stable or increased post-treatment KPS independently predicted better OS (P = 0.018, P = 0.014, P = 0.014, and P = 0.001). After PSM in non-oligometastatic patients, a higher radiation dose (≥63 Gy) remained to be correlated with better OS. By landmark analysis, aggressive radiation (≥63 Gy) remained to be correlated with better OS in Pre-PSM cohort (P = 0.005) and Post-PSM cohort (P = 0.004). Radiation dose, primary tumor volume, response to chemotherapy and KPS after treatment are associated with OS in patients with non-oligometastatic disease; on basis of effective system chemotherapy, aggressive thoracic radiotherapy may prolong OS.

23 April 2025 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
LLLan Luo
Lan Luo
ZLZhu Liu
Zhu Liu
QGQuan Gan
Quan Gan
JFJing Feng
Jing Feng
LWLingyun Wang
Lingyun Wang
WOWeiwei Ouyang
Weiwei Ouyang
The degree to which the triglyceride-glucose (TyG) index might interact with colorectal cancer (CRC) incidence and mortality is undefined. This systematic analysis was conducted through meta-analyses and large-scale databases. A meta-analysis was conducted through database search up to April 1, 2025, and articles investigating the incidence of CRC with clearly reported TyG index values, focusing on their dose-response relationship, were included. To validate the findings, data from the 1999–2018 National Health and Nutrition Examination Survey (NHANES) were utilized to explore links of TyG levels with CRC-linked mortality. Analyses involving restricted cubic splines (RCSs), weighted logistic regression (WLR), and multivariate Cox proportional hazards models were performed. Receiver operating characteristic (ROC) analyses explored predictive potential. Subgroup evaluation was subsequently conducted for detecting the susceptible populations. Multivariate logistic regression showcased a greater CRC incidence among individuals in quartiles two, three, and four of TyG and TyG-body mass index (TyG-BMI) (95% confidence intervals (CIs): 1.14–1.5, 1.07–1.45; 1.39–1.83, 1.11–1.64; and 1.60–2.12, 1.19–1.93, respectively; P < 0.001). In contrast, multivariate Cox regression indicated a significant increase in CRC-related mortality only in the second quartile of TyG (95% CI: 1.22–7.47; P < 0.05). Analysis of the RCS curves demonstrated that the incidence of CRC displayed a nonlinear association with TyG (P = 0.045 for nonlinearity) but a positive linear association with TyG-BMI (P = 0.385 for nonlinearity). The TyG and associated indices did not exhibit any obvious dose-response association with CRC-related mortality (P > 0.05). ROC analyses exploring CRC risk revealed that TyG-BMI outperformed all indicators (area under the curve (AUC) = 0.71). Subgroup analysis revealed statistically significant links of CRC incidence with both TyG-BMI and female sex. TyG and TyG-BMI may function as dependable markers for predicting CRC likelihood, and TyG-BMI outperformed all other predictors considered herein. However, TyG and associated indices showed no significant interrelationships with the mortality of CRC.

18 December 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
SSShengFa Su
ShengFa Su
YHYinXiang Hu
YinXiang Hu
WOWeiwei Ouyang
Weiwei Ouyang
ZMZhu Ma
Zhu Ma
BLBing Lu
Bing Lu
YWYu Wang
Yu Wang
The impact of thoracic three-dimensional radiotherapy on the prognosis for stage IV non-small-cell lung cancer is unclear. This study is to investigate survival outcomes and prognosis in patients with stage IV non-small cell lung cancer (NSCLC) treated with thoracic three-dimensional radiotherapy and systemic chemotherapy. Ninety three patients with stage IV NSCLC had received at least four cycles of chemotherapy and thoracic three-dimensional radiotherapy of ≥40 Gy on primary tumors. The data from these patients were retrospectively analyzed. Of the 93 patients, the median survival time (MST) was 14.0 months, and the 1, 2, and 3-year survival rates were 54.8%, 20.4%, and 12.9%, respectively. The MST of patients received radiation dose to primary tumor ≥63Gy and <63 Gy for primary tumor were 15.0 and 8.0 months, respectively (P = 0.001). Patients had metastasis to a single site and lower tumor volume (<170 cm3) also produced longer overall survival time (P = 0.002, P = 0.020, respectively). For patients with metastasis at a single site, thoracic radiation dose ≥63 Gy remained a prognostic factor for better overall survival (P = 0.030); patients with metastases at multiple sites, radiation dose ≥63 Gy had a trend to improve overall survival (P = 0.062). A multivariate analysis showed that radiation dose ≥63 Gy (P = 0.017) and metastasis to a single site (P = 0.038) are associated with better overall survival, and the volume of primary tumor was marginally correlated with OS (P = 0.054). In combination with systemic chemotherapy, radiation dose ≥63 Gy on primary tumor and metastasis to a single site are significant factors for better OS, aggressive thoracic radiotherapy may have an important role in improving OS.

8 July 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WOWeiwei Ouyang
Weiwei Ouyang
SSSheng-Fa Su
Sheng-Fa Su
YHYin-Xiang Hu
Yin-Xiang Hu
BLBing Lu
Bing Lu
ZMZhu Ma
Zhu Ma
YGYi-Chao Geng
Yi-Chao Geng
The objective of this study was to evaluate the radiation dose and response in terms of local-regional progression-free survival (LRPFS) and overall survival (OS) of patients with stage IV non-small cell lung cancer (NSCLC) undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy.

24 June 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
WOWeiwei Ouyang
Weiwei Ouyang
SSSheng-Fa Su
Sheng-Fa Su
ZMZhu Ma
Zhu Ma
YHYin-Xiang Hu
Yin-Xiang Hu
BLBing Lu
Bing Lu
HLHui-Qin Li
Hui-Qin Li
To evaluate the efficacy of three-dimensional radiotherapy for non-small cell lung cancer (NSCLC) patients with bone metastases.